Perrigo Company plc (NYSE:PRGO) Receives Average Rating of “Reduce” from Brokerages

Perrigo Company plc (NYSE:PRGO) has been given a consensus rating of “Reduce” by the six brokerages that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $19.3333.

A number of research analysts recently issued reports on PRGO shares. Jefferies Financial Group restated a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. Argus upgraded shares of Perrigo to a “hold” rating in a research report on Wednesday, January 14th. Zacks Research downgraded shares of Perrigo from a “hold” rating to a “strong sell” rating in a research report on Friday, March 20th. Canaccord Genuity Group decreased their price objective on shares of Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Perrigo in a research report on Monday, December 22nd.

Perrigo Trading Up 2.1%

NYSE PRGO opened at $12.05 on Tuesday. The company has a market capitalization of $1.66 billion, a PE ratio of -1.17, a P/E/G ratio of 1.38 and a beta of 0.47. The company has a fifty day moving average of $11.63 and a 200 day moving average of $14.36. Perrigo has a 1 year low of $9.23 and a 1 year high of $28.43. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.76 and a quick ratio of 1.63.

Perrigo (NYSE:PRGO) last posted its earnings results on Thursday, February 26th. The company reported $0.77 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. The company’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.93 earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Research analysts forecast that Perrigo will post 2.13 earnings per share for the current year.

Perrigo Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 24th. Shareholders of record on Monday, March 2nd were given a $0.29 dividend. The ex-dividend date was Monday, March 2nd. This represents a $1.16 dividend on an annualized basis and a dividend yield of 9.6%. Perrigo’s dividend payout ratio is -11.28%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PRGO. Amundi raised its position in shares of Perrigo by 11.7% in the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after acquiring an additional 556 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Perrigo by 126.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after acquiring an additional 647,982 shares during the period. United Services Automobile Association acquired a new position in shares of Perrigo in the first quarter worth about $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Perrigo by 6.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock worth $14,388,000 after acquiring an additional 32,151 shares during the period. Finally, Geneos Wealth Management Inc. raised its position in shares of Perrigo by 439.1% in the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after acquiring an additional 786 shares during the period. Institutional investors and hedge funds own 95.91% of the company’s stock.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.